Literature DB >> 17464267

Somatostatin receptor PET imaging with Gallium-68 labeled peptides.

Z Win1, A Al-Nahhas, D Rubello, M D Gross.   

Abstract

Imaging somatostatin receptor status with 68Ga labeled peptides has progressed rapidly over the last several years. It has generated great interest, and stimulated further research into the development of DOTA-derivative peptides. It has expanded our knowledge of receptor imaging and enhanced our appreciation of the difference between receptor-based and metabolic imaging, as well as more in-depth evaluation of tumor biology. The availability of the 68Ge/68Ga generator provides an attractive alternative to cyclotron-based positron-emitters, especially if kit-based radiopharmaceutical formulations based upon 68Ga are developed in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17464267

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  5 in total

Review 1.  Labeling peptides with PET radiometals: Vulcan's forge.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01       Impact factor: 9.236

Review 2.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

3.  Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?

Authors:  Akram Al-Ibraheem; Ralph Alexander Bundschuh; Johannes Notni; Andreas Buck; Anna Winter; Hans-Jürgen Wester; Markus Schwaiger; Klemens Scheidhauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-27       Impact factor: 9.236

Review 4.  Positron emission tomography image-guided drug delivery: current status and future perspectives.

Authors:  Rubel Chakravarty; Hao Hong; Weibo Cai
Journal:  Mol Pharm       Date:  2014-06-04       Impact factor: 4.939

5.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.